Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Recombinant follistatin counteracts tumor effects on myotubes exclusively by rescuing fusion index, suggesting that it is only partially responsible for the stretch-mediated rescue.
|
31068826 |
2019 |
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
We investigated Activin A and Follistatin in serum and tumor tissue of patients with TETs in relation to microvessel density (MVD), WHO histology classification, tumor stage and outcome.
|
31757999 |
2019 |
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Analysis of activin- and follistatin-expressing R30C cells identified a cell autonomous role of this system in controlling tumor cell growth.
|
16740706 |
2006 |
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
We also investigated tumor expression of follistatin messenger ribonucleic acid, an activin-binding protein with two isoforms of different potencies.
|
10720031 |
2000 |
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
These results suggest that FST may play an important role in exhibiting stronger tumoricidal ability in rat UCMSC than human UCMSC and also implies that human UCMSC can be transformed into stronger tumoricidal cells by enhancing tumor suppressor gene expression.
|
25942583 |
2015 |
Neoplasms
|
0.100 |
PosttranslationalModification
|
group |
BEFREE |
Tumor samples revealed that methylation at the transmembrane protein containing epidermal growth factor and follistatin domains (TPEF) locus had the best ratio of discrimination between tumor samples versus normal tissues (83 versus 0%).
|
15068392 |
2003 |
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
These genes are functionally involved with virus process (F13A1 and HSP90AB1), immunity (ABCB1LB, RGS5, C10ORF58, OSF-2, MMP7, CXCL12, GAL1, GAL2, GAL7, HVCN1, PDE4D, IL4I1, PARP9, EOMES, MPEG1, PDK4, CCLI10, K60 and FST), and tumor suppression (ADAMTS2, LXN, ARRDC3, WNT7A, CLDN1 and HPGD).
|
31578366 |
2019 |
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Association of serum follistatin levels with histological types and progression of tumor in human lung cancer.
|
30377409 |
2018 |
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Absence of FSH, lack of androgen receptor, or overexpression of follistatin slows the tumor growth and minimizes the cachexia symptoms, thus prolonging the life span of these double mutant mice.
|
12760377 |
2003 |
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
However, expression of follistatin in tumor was not correlated with overall survival or disease-free survival.
|
20309641 |
2010 |
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The transmembrane protein with a single EGF-like and two follistatin domains (TMEFF2) is epigenetically silenced in numerous tumor types, suggesting a potential role as a potential tumor suppressor.
|
22814847 |
2012 |
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
These findings suggest that follistatin expression in invasive breast cancer is unrelated to the disease severity and the risk of recurrence, but is more intense in ER-negative tumors.
|
27389553 |
2018 |
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Approximately 40% of the tumors (nine of 24 each), most of them hepatocellular carcinomas, displayed increased levels of follistatin mRNA when compared to tumor-surrounding liver tissue.
|
12203361 |
2002 |
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Clinical and Therapeutic Implications of Follistatin in Solid Tumours.
|
27807065 |
2017 |
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
These data are the first to demonstrate that 1) endogenous inhibin subunits are synthesized in human pituitary adenomas of all known secretory phenotypes as well as normal pituitary tissue; and 2) follistatin gene expression in pituitary adenomas is specific to clinically nonfunctioning or gonadotropin subunit-producing tumors.
|
7829603 |
1995 |
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
In contrast, total inhibin was secreted by only 2/25 (range 0.01-0.92 ng/mL), whereas free FS was not detectable in the medium of any tumor (< 0.5 ng/mL).
|
9360531 |
1997 |
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Expression of the activin receptor type II and follistatin genes suggests a paracrine role for activin in these tumors which may be modulated by follistatin, particularly in the GCT.
|
10329046 |
1999 |